AU2022389558A1 - Kif18a inhibitor - Google Patents
Kif18a inhibitor Download PDFInfo
- Publication number
- AU2022389558A1 AU2022389558A1 AU2022389558A AU2022389558A AU2022389558A1 AU 2022389558 A1 AU2022389558 A1 AU 2022389558A1 AU 2022389558 A AU2022389558 A AU 2022389558A AU 2022389558 A AU2022389558 A AU 2022389558A AU 2022389558 A1 AU2022389558 A1 AU 2022389558A1
- Authority
- AU
- Australia
- Prior art keywords
- hydrocarbyl
- compound
- int
- mmol
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111399876 | 2021-11-19 | ||
| CN202111399876.4 | 2021-11-19 | ||
| CN202210225663.8 | 2022-03-09 | ||
| CN202210225663 | 2022-03-09 | ||
| CN202210667619 | 2022-06-13 | ||
| CN202210667619.2 | 2022-06-13 | ||
| PCT/CN2022/132954 WO2023088441A1 (zh) | 2021-11-19 | 2022-11-18 | Kif18a抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022389558A1 true AU2022389558A1 (en) | 2024-05-23 |
Family
ID=86396297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022389558A Pending AU2022389558A1 (en) | 2021-11-19 | 2022-11-18 | Kif18a inhibitor |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260158017A1 (enExample) |
| EP (1) | EP4434979A4 (enExample) |
| JP (1) | JP2024542199A (enExample) |
| KR (1) | KR20240108489A (enExample) |
| CN (1) | CN118215657A (enExample) |
| AU (1) | AU2022389558A1 (enExample) |
| CA (1) | CA3237625A1 (enExample) |
| MX (1) | MX2024005996A (enExample) |
| WO (1) | WO2023088441A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| KR20240109977A (ko) | 2021-08-26 | 2024-07-12 | 볼라스트라 쎄라퓨틱스, 인코포레이티드 | Kif18a의 스피로 인돌린 억제제 |
| WO2024022508A1 (zh) * | 2022-07-29 | 2024-02-01 | 武汉人福创新药物研发中心有限公司 | Kif18a抑制剂及用途 |
| CR20250087A (es) | 2022-08-18 | 2025-07-11 | Accent Therapeutics Inc | Inhibidores de kif18a y usos de estos |
| CN117917405A (zh) * | 2022-10-21 | 2024-04-23 | 杭州邦顺制药有限公司 | Kif18a蛋白抑制剂 |
| WO2024114730A1 (zh) * | 2022-11-30 | 2024-06-06 | 微境生物医药科技(上海)有限公司 | 一种用于癌症治疗的药物组合物 |
| JP2026508745A (ja) * | 2022-12-02 | 2026-03-12 | シェンチェン ジョングァー バイオロジカル テクノロジー カンパニー リミテッド | アミド又はウレア系化合物 |
| CN120569373A (zh) * | 2023-01-05 | 2025-08-29 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和医药上的用途 |
| WO2024244972A1 (zh) * | 2023-05-30 | 2024-12-05 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| EP4748837A1 (en) * | 2023-07-21 | 2026-05-27 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Aromatic amide derivative, and preparation method therefor and use thereof |
| CN121752573A (zh) * | 2023-08-02 | 2026-03-27 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| CN121693499A (zh) * | 2023-08-16 | 2026-03-17 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2025190888A1 (en) * | 2024-03-12 | 2025-09-18 | F. Hoffmann-La Roche Ag | Macrocyclic kif18a inhibitors and their use thereof |
| WO2025201407A1 (zh) * | 2024-03-27 | 2025-10-02 | 上海齐鲁制药研究中心有限公司 | 驱动蛋白kif18a抑制剂及其使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| MA54550A (fr) * | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| AU2019401495B2 (en) * | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| AU2019404576B2 (en) * | 2018-12-20 | 2025-07-17 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| AU2020325115B2 (en) * | 2019-08-02 | 2026-03-12 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
| JP7699100B2 (ja) * | 2019-08-02 | 2025-06-26 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| US20220289724A1 (en) * | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
| JP2023521802A (ja) * | 2020-04-14 | 2023-05-25 | アムジエン・インコーポレーテツド | 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤 |
| KR20240070604A (ko) * | 2021-09-24 | 2024-05-21 | 제논 파마슈티칼스 인크. | 소듐 채널 활성화제로서 피리디닐아세트아미드 유도체 |
-
2022
- 2022-11-18 MX MX2024005996A patent/MX2024005996A/es unknown
- 2022-11-18 EP EP22894970.7A patent/EP4434979A4/en active Pending
- 2022-11-18 AU AU2022389558A patent/AU2022389558A1/en active Pending
- 2022-11-18 CA CA3237625A patent/CA3237625A1/en active Pending
- 2022-11-18 WO PCT/CN2022/132954 patent/WO2023088441A1/zh not_active Ceased
- 2022-11-18 JP JP2024529504A patent/JP2024542199A/ja active Pending
- 2022-11-18 KR KR1020247020178A patent/KR20240108489A/ko active Pending
- 2022-11-18 CN CN202280076424.9A patent/CN118215657A/zh active Pending
- 2022-11-18 US US18/706,640 patent/US20260158017A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023088441A1 (zh) | 2023-05-25 |
| MX2024005996A (es) | 2024-05-30 |
| KR20240108489A (ko) | 2024-07-09 |
| CA3237625A1 (en) | 2023-05-25 |
| CN118215657A (zh) | 2024-06-18 |
| JP2024542199A (ja) | 2024-11-13 |
| US20260158017A1 (en) | 2026-06-11 |
| EP4434979A4 (en) | 2025-10-29 |
| EP4434979A1 (en) | 2024-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113024544B (zh) | 一种含氰基并杂环化合物及其用途 | |
| AU2021323304B2 (en) | Compound for targeting and degrading protein, and preparation method therefor and use thereof | |
| AU2023236101A1 (en) | Kif18a inhibitor | |
| AU2020280699B2 (en) | Compound used as RET kinase inhibitor and application thereof | |
| EP4434979A1 (en) | Kif18a inhibitor | |
| CN112745335B (zh) | 一种三并杂环化合物及其用途 | |
| CN117143107A (zh) | 1,2-二氢吡啶类衍生物及其制备方法和用途 | |
| AU2017206382C1 (en) | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | |
| CN116583502A (zh) | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 | |
| CN112707905B (zh) | 一种三并杂环化合物及其制备方法和用途 | |
| CN112851663B (zh) | 一种并杂环化合物及其用途 | |
| AU2023299816A1 (en) | Nitrogen-containing compound and use thereof | |
| AU2021394411A1 (en) | Novel camptothecin derivative, composition containing same, and use thereof | |
| US20230373989A1 (en) | N-phenylaminocarbonyl pyridino-, pyrimidino and benzo-tropanes as modulators of gpr65 | |
| AU2021276206B2 (en) | Compound used as RET kinase inhibitor and application thereof | |
| CN118076586A (zh) | Kif18a抑制剂 | |
| AU2020346936B2 (en) | Novel tricyclic aromatic heterocyclic compound, preparation method therefor, pharmaceutical composition and application thereof | |
| AU2023378332A1 (en) | Fused bicyclic compound | |
| CN120202002A (zh) | 一种用于癌症治疗的药物组合物 | |
| WO2024114704A1 (zh) | 新型irak4抑制剂以及抑制并降解irak4蛋白的化合物及其制备方法和应用 | |
| CN118108704A (zh) | Kif18a抑制剂 | |
| CN119998274A (zh) | Ulk抑制剂 | |
| AU2023348878A1 (en) | Compound as inhibitor for sumo activating enzyme | |
| CN120693323A (zh) | Kif18a抑制剂 | |
| KR20250052447A (ko) | Jak 키나아제 억제제의 전구체 약물 |